Significantly greater expression of CD133 in tissues was seen in melanoma patients who developed metastatic lesions/recurrence of the disease, when compared with the group of melanoma patients who did not develop any metastatic lesions or recurrence (p<0.02, Fisher’s exact test; Table I). The gene discussed is PROM1; the disease is melanoma.